How should a breast fibroepithelial lesion be evaluated and managed?

Management of Breast Fibroepithelial Lesions

When a fibroepithelial lesion is diagnosed on core needle biopsy, select patients may be suitable for imaging surveillance rather than automatic surgical excision, particularly when the lesion is small (≤4.5 cm), has homogeneous echo pattern on ultrasound, and lacks concerning histologic features such as stromal overgrowth. 1

Initial Evaluation and Diagnosis

Core Needle Biopsy Findings

• Core needle biopsy is the preferred diagnostic method over fine-needle aspiration for tissue diagnosis of suspected fibroepithelial lesions 1
• Image-guided biopsy (ultrasound or stereotactic) is superior to palpation-guided biopsy, allowing confirmation of sampling accuracy and marker clip placement 1

Risk Stratification After Biopsy

High-Risk Features Requiring Surgical Excision:

• Indeterminate lesions or benign lesions that are image-discordant 1
• Potential phyllodes tumor (mucin-producing lesions, papillary lesions, radial scars, or other histologies of concern to the pathologist) 1
• Pathologist comment "cannot rule out phyllodes tumor" or "favors phyllodes tumor" 2, 3
• Concerning histologic features: mitoses, stromal overgrowth, increased cellularity, or leaf-like architecture 2
• Size >4.5 cm 2
• Heterogeneous echo pattern on ultrasound 2

Low-Risk Features Suitable for Surveillance:

• Benign fibroepithelial lesion that is image-concordant 1
• Size ≤4.5 cm with homogeneous echo pattern and absence of stromal overgrowth (SHO score = 0, which carries only 1% risk of borderline/malignant phyllodes tumor) 2
• Lesions <2 cm with low clinical suspicion 1

Management Algorithm

For Benign, Image-Concordant Fibroepithelial Lesions:

Option 1: Active Surveillance 1

• Physical examination with or without ultrasound or mammogram every 6-12 months for 1-2 years to assess stability 1
• If stable: return to routine breast screening 1
• If significant increase in size or suspicion: proceed to surgical excision 1

Option 2: Surgical Excision 1

• Appropriate for symptomatic lesions, patient preference, or concerning features 4

Natural History Under Surveillance:

• 98% of excised fibroepithelial lesions prove benign (fibroadenoma, benign phyllodes tumor, or benign breast tissue) 4
• Under active surveillance, only 35% increase in volume by ≥50% at 2 years, with the majority remaining stable or decreasing 4
• All lesions that were initially observed and later excised were benign 4

Critical Pitfalls to Avoid

Radiologic-Pathologic Concordance

• Always verify concordance between imaging findings and biopsy results before deciding on surveillance 1
• Discordant findings mandate surgical excision regardless of benign pathology 1

Size Considerations

• Larger lesions (>4.5 cm) have significantly higher risk of borderline/malignant phyllodes tumor (median 3.9 cm vs 1.3 cm for benign lesions) 2, 4
• Size should be factored into the decision for excision versus surveillance 2, 3

Pathology Report Interpretation

• "Fibroepithelial lesion-not further characterized" (FEL-NFC) requires careful evaluation of both imaging and histologic features 2
• Comments suggesting phyllodes tumor or describing stromal features (overgrowth, hypercellularity, atypia) should prompt excision 2, 3

Follow-Up Compliance

• Surveillance is only appropriate when reliable follow-up can be ensured 4
• Mean follow-up of 30 months showed no disease progression in appropriately selected patients 3

Special Populations

Women <30 Years

• Ultrasound is the preferred initial imaging modality 1
• Observation for 1-2 menstrual cycles is acceptable for low clinical suspicion lesions 1
• Mammography reserved for highly suspicious findings or high-risk patients 1

Women ≥30 Years

• Diagnostic mammogram is the initial evaluation, followed by ultrasound for BI-RADS 1-3 findings 1
• Observation without evaluation is not appropriate 1